Formulation Development
Quotient Sciences Announces Major Investment in Sterile Fill/Finish Capacity in Response to Increasing Industry Demand
Quotient Sciences recently announced it has made a major investment in the sterile fill/finish capabilities at its Alnwick, UK, facility. This investment will increase the…
Flashpoint Therapeutics Announces $10M Seed Financing to Pioneer Nanotechnology-Enabled Medicines
Flashpoint Therapeutics recently announced $10M seed financing round led by Beta Lab, a leading deep tech venture capital firm headquartered in Riyadh, Saudi Arabia, with…
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics, Inc. recently announced the US FDA has provided clearance of the company’s Investigational New Drug (IND) application to initiate clinical testing of TN-401.…
ABVC BioPharma Entered a Term Sheet to License Global Rights of CNS Drugs With the Indications of MDD & ADHD to AiBtl BioPharma at $667-Million Valuation
ABVC BioPharma, Inc. recently announced it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with AiBtl BioPharma (AiBtl) for the company’s CNS drugs with the indications of….
Pfizer & BioNTech Announce Positive Topline Data for mRNA-Based Combination Vaccine Program Against Influenza & COVID-19
Pfizer Inc. and BioNTech SE recently announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability, and immunogenicity of mRNA-based combination vaccine candidates…
Orchard Therapeutics Announces Additional Positive Data from Proof-of-Concept Study of OTL-203 in MPS-IH
Orchard Therapeutics recently announced a range of interim clinical outcomes, in addition to the previously reported neurological and skeletal results, from the company’s ongoing proof-of-concept…
Andelyn Biosciences & Purespring Therapeutics Partner to Manufacture Novel Gene Therapies for Kidney Diseases
Andelyn Biosciences, Inc. has recently partnered with Purespring Therapeutics to accelerate the manufacture of their gene therapies for the treatment of chronic renal diseases that…
Aldena Therapeutics Selects PCI Pharma Services to Manufacture & Distribute Innovative Investigational Treatment for Dermatological Diseases
Aldena Therapeutics has chosen PCI Pharma Services (PCI) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for….
WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy
Direct compression is often used for tablet manufacturing because it is the shortest, most effective, and least complex method. The physical properties of active pharmaceutical…
Evonik Launches EUDRACAP Preclinic Functional Oral Capsule for Preclinical Trials
Evonik is launching a functional, ready-to-fill oral capsule designed for use in preclinical trials. EUDRACAP preclinic enteric is a very small size 9h (5.1 mm),…
Ovid Therapeutics & Ligand Pharmaceuticals Enter $30-Million Agreement
Ovid Therapeutics Inc. and Ligand Pharmaceuticals Incorporated recently announced Ligand has acquired a 13% portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of….
IMUNON Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. recently announced the first patient in a Phase 1/2 clinical trial evaluating IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun…
Lisata Therapeutics Announces EMA Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
Lisata Therapeutics, Inc. recently announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted orphan drug designation to LSTA1, the company’s lead…
Monte Rosa Therapeutics Announces Strategic Collaboration With Roche
Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEEN discovery engine with Roche’s strong expertise in delivering transformative therapies to patients….
Lumen Bioscience Awarded $16.2 Million in DoD Funding to Advance LMN-201 Through Late-Stage Trials
Lumen Bioscience recently announced it was awarded $16.2 million by the US Department of Defense to advance LMN-201 through late-stage trials. LMN-201 is an investigational,…
Elevar Therapeutics & Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement
Elevar Therapeutics, Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd. recently announced a global licensing agreement that grants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody camrelizumab in combination with….
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase 2b Clinical Study
ABVC BioPharma, Inc. recently announced an update on the company's 8-week long ADHD Phase 2b clinical study taking place at the University of California San…
GRI Bio Announces Partnership With the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
GRI Bio, Inc. recently announced it has entered into a collaboration with the UK consortia, National Institute for Health and Care Research Respiratory Translational Research…
Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO
Quotient Sciences recently announce the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective October 16, 2023. Thierry succeeds Mark Egerton who….
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
Terns Pharmaceuticals, Inc. recently announced the US FDA’s clearance of its Investigational New Drug application and the design of the CARDINAL Trial, Terns’ global Phase…